keyword
MENU ▼
Read by QxMD icon Read
search

neutrophil-to-lymphocyte ratio And Pancreatic Cancer

keyword
https://read.qxmd.com/read/30836428/association-of-preoperative-total-lymphocyte-count-with-prognosis-in-resected-left-sided-pancreatic-cancer
#1
Seoung Yoon Rho, Ho Kyoung Hwang, Jae Uk Chong, Dong Sup Yoon, Woo Jung Lee, Chang Moo Kang
BACKGROUND: Immunologic factors such as neutrophil-lymphocyte ratio and platelet-lymphocyte ratio play an important role in predicting the oncologic outcome of patients in pancreatic ductal adenocarcinoma (PDAC). It is hypothesized that host immunity represented by total lymphocyte count at diagnostic stage would influence oncologic outcome in left-sided PDAC. METHODS: Between January 1992 and August 2017, total of 112 patients who underwent distal pancreatectomy for left-sided PDAC were included and analysed...
March 5, 2019: ANZ Journal of Surgery
https://read.qxmd.com/read/30765142/low-lymphocyte-monocyte-ratio-after-neoadjuvant-therapy-predicts-poor-survival-after-pancreatectomy-in-patients-with-borderline-resectable-pancreatic-cancer
#2
Manabu Kawai, Seiko Hirono, Ken-Ichi Okada, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Ryohei Kobayashi, Masaki Ueno, Shinya Hayami, Kensuke Tanioka, Hiroki Yamaue
BACKGROUND: The impact of systemic immune inflammatory markers to predict survival in patients receiving neoadjuvant therapy for borderline resectable pancreatic cancer has not been sufficiently investigated. This study aims to evaluate whether systemic immune inflammatory markers after neoadjuvant therapy followed by pancreatectomy become preoperative prognostic factors to predict survival in patients with borderline resectable pancreatic cancer. METHODS: We retrospectively reviewed 67 borderline resectable pancreatic cancer patients receiving neoadjuvant therapy and 58 borderline resectable pancreatic cancer patients undergoing upfront surgery between 2010 and 2016...
February 11, 2019: Surgery
https://read.qxmd.com/read/30719874/the-impact-study-early-loss-of-skeletal-muscle-mass-in-advanced-pancreatic-cancer-patients
#3
Debora Basile, Annamaria Parnofiello, Maria Grazia Vitale, Francesco Cortiula, Lorenzo Gerratana, Valentina Fanotto, Camilla Lisanti, Giacomo Pelizzari, Elena Ongaro, Michele Bartoletti, Silvio Ken Garattini, Victoria Josephine Andreotti, Anna Bacco, Donatella Iacono, Marta Bonotto, Mariaelena Casagrande, Paola Ermacora, Fabio Puglisi, Nicoletta Pella, Gianpiero Fasola, Giuseppe Aprile, Giovanni G Cardellino
BACKGROUND: Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and worse prognosis. METHODS: This is a retrospective study on advanced PC patients treated at the Department of Oncology of Udine, Italy, from January 2012 to November 2017. Among 162 patients who received chemotherapy, 94 consecutive patients with an available computed tomography (CT) scan were retrospectively analyzed...
February 4, 2019: Journal of Cachexia, Sarcopenia and Muscle
https://read.qxmd.com/read/30654298/napoli-1-phase-3-study-of-liposomal-irinotecan-in-metastatic-pancreatic-cancer-final-overall-survival-analysis-and-characteristics-of-long-term-survivors
#4
Andrea Wang-Gillam, Richard A Hubner, Jens T Siveke, Daniel D Von Hoff, Bruce Belanger, Floris A de Jong, Beloo Mirakhur, Li-Tzong Chen
BACKGROUND: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. This approval was based on significantly improved median overall survival compared with 5-FU/LV alone (6.1 vs 4.2 months; hazard ratio [HR], 0.67) in the global phase 3 NAPOLI-1 trial. Here, we report the final survival analysis and baseline characteristics associated with long-term survivors (survival of ≥1 year) in the NAPOLI-1 trial...
January 14, 2019: European Journal of Cancer
https://read.qxmd.com/read/30643364/molecular-detection-of-epithelial-mesenchymal-transition-markers-in-circulating-tumor-cells-from-pancreatic-cancer-patients-potential-role-in-clinical-practice
#5
Xiao-Hui Zhao, Zai-Rui Wang, Chang-Long Chen, Ling Di, Zhuo-Fei Bi, Zhi-Hua Li, Yi-Min Liu
AIM: To evaluate the clinical properties of three subpopulations of circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) patients. METHODS: We identified CTCs for expression of the epithelial cell marker cytokeratin or epithelial cell adhesion molecule (EpCAM) (E-CTC), the mesenchymal cell markers vimentin and twist (M-CTC), or both (E/M-CTC) using the CanPatrol system. Between July 2014 and July 2016, 107 patients with PDAC were enrolled for CTC evaluation...
January 7, 2019: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/30636977/predicting-mortality-and-adverse-events-in-patients-with-advanced-pancreatic-cancer-treated-with-palliative-gemcitabine-based-chemotherapy-in-a-multicentre-phase-iii-randomized-clinical-trial-the-apc-sakk-risk-scores
#6
Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, Peter Brauchli
Background: The prognosis of advanced pancreatic cancer (APC) is poor and differs considerably among patients. Therefore, it is clinically relevant to identify patients with APC who are more likely to benefit from palliative chemotherapy with reduced risk of toxicity. To date, there is no prognostic score universally recommended to help clinicians in planning the therapeutic management. Methods: Using individual patient data from 319 cases of APC treated with gemcitabine-based chemotherapy and enrolled in the SAKK 44/00-CECOG/PAN...
2019: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30634387/prognostic-factors-for-advanced-pancreatic-cancer-treated-with-gemcitabine-plus-s-1-retrospective-analysis-and-development-of-a-prognostic-model
#7
Ching-Fu Chang, Pei-Wei Huang, Jen-Shi Chen, Yen-Yang Chen, Chang-Hsien Lu, Pei-Hung Chang, Yu-Shin Hung, Wen-Chi Chou
Gemcitabine plus S-1 (GS) is commonly used to treat advanced pancreatic cancer (APC) in Asia. Few clinical experiments have demonstrated the clinical efficacy of GS in routine clinical practice. We aimed to identify the prognostic factors and develop a prognostic model for survival prediction in patients with APC, treated with GS. Records of 111 patients with newly diagnosed APC who received first-line palliative GS chemotherapy during 2010⁻2016 in Taiwan were analyzed retrospectively. Univariate and multivariate analyses were performed for the identification of prognostic factors...
January 9, 2019: Cancers
https://read.qxmd.com/read/30632282/preoperative-c-reactive-protein-to-albumin-ratio-is-a-predictor-of-survival-after-pancreatic-resection-for-pancreatic-ductal-adenocarcinoma
#8
Shinichi Ikuta, Tsukasa Aihara, Naoki Yamanaka
AIM: Systemic inflammation and nutritional status are associated with clinical outcomes of cancer patients. We investigated the prognostic value of preoperative C-reactive protein to albumin ratio (CAR) in patients with pancreatic ductal adenocarcinoma (PDA) after pancreatic resection. METHODS: One-hundred and thirty-six PDA patients who underwent pancreatic resection between January 2005 and June 2017 were retrospectively enrolled. Preoperative inflammation-based scores including CAR, modified Glasgow prognostic score (mGPS), neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, lymphocyte to monocyte ratio (LMR) and prognostic nutritional index (PNI) were evaluated as potential predictor of overall survival (OS) using Cox regression models...
January 10, 2019: Asia-Pacific Journal of Clinical Oncology
https://read.qxmd.com/read/30505600/the-accuracy-of-neutrophil-to-lymphocyte-ratio-and-platelet-to-lymphocyte-ratio-as-a-marker-for-gastrointestinal-malignancies
#9
Ian Nora, Ravi Shridhar, Jamie Huston, Kenneth Meredith
Background: Accurate predictors of locally advanced and recurrence disease in patients with gastrointestinal cancer are currently lacking. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have emerged as possible markers for predicting recurrence in these patients. In this study, we sought to evaluate the utility of NLR and PLR in predicting the presence of regional nodal disease, metastasis and systemic recurrence in patients with gastrointestinal malignancies...
October 2018: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/30396977/c-reactive-protein-based-prognostic-measures-are-superior-at-predicting-survival-compared-with-peripheral-blood-cell-count-based-ones-in-patients-after-curative-resection-for-pancreatic-cancer
#10
COMPARATIVE STUDY
Yuki Fujiwara, Koichiro Haruki, Hiroaki Shiba, Ryoga Hamura, Takashi Horiuchi, Yoshihiro Shirai, Kenei Furukawa, Takeshi Gocho, Katsuhiko Yanaga
AIM: Prognostic factors of recurrence and survival in various cancer types have been reported and include C-reactive protein (CRP)-based measures as evidenced by the Glasgow prognostic score (GPS), as well as peripheral blood cell-based prognostic values such as the prognostic index (PI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). The aim of this study was to identify significant prognostic values and compare them for suitability for use in patients after curative pancreatic resection for pancreatic cancer...
November 2018: Anticancer Research
https://read.qxmd.com/read/30360017/inflammatory-markers-as-prognostic-indicators-in-pancreatic-cancer-patients-who-underwent-gemcitabine-based-palliative-chemotherapy
#11
Hong Jun Kim, Suk-Young Lee, Dae Sik Kim, Eun Joo Kang, Jung Sun Kim, Yoon Ji Choi, Sang Cheul Oh, Jae Hong Seo, Jun Suk Kim
Background/Aims: Patients with pancreatic cancer (PC) generally have poor clinical outcomes. Early determination of their prognosis is crucial for developing a therapeutic strategy. Recently, various inflammatory markers have been validated as prognostic indicators for many cancers, including PC. However, few studies have evaluated these markers together. Thus, the purpose of this study was to comprehensively evaluate the value of inflammatory markers as prognostic indicators in patients with advanced PC treated with gemcitabine-based chemotherapy as the first line regimen...
October 26, 2018: Korean Journal of Internal Medicine
https://read.qxmd.com/read/30233792/neutrophil-to-lymphocyte-ratio-as-a-predictor-of-postoperative-morbidity-in-patients-with-distal-cholangiocarcinoma
#12
Yusuke Kumamoto, Takashi Kaizu, Hiroshi Tajima, Nobuyuki Nishizawa, Shigenori Ei, Kazuharu Igarashi, Masahiko Watanabe
Systemic inflammatory-, immunological- and nutritional-based indices, such as the neutrophil-to-lymphocyte ratio (NLR), the prognostic nutritional index (PNI) and the Glasgow prognostic score (GPS), are drawing considerable research attention to predict the long-term prognosis of many types of cancer. Recently, these parameters have also been reported to be useful in predicting postoperative morbidity in several fields, including colorectal and otolaryngological cancer. However, while distal cholangiocarcinoma exhibits a high morbidity rate, its risk factors of morbidity have not yet been established...
October 2018: Molecular and Clinical Oncology
https://read.qxmd.com/read/30230959/long-term-survival-of-pancreatic-cancer-patients-treated-with-multimodal-therapy-combined-with-wt1-targeted-dendritic-cell-vaccines
#13
Shuichi Hanada, Tomoko Tsuruta, Kouichi Haraguchi, Masato Okamoto, Haruo Sugiyama, Shigeo Koido
BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDA) remains one of the most aggressive tumors with a dismally poor prognosis. Although surgical resection remains the only potentially curative treatment, most PDAs are not surgically resectable at diagnosis. Therefore, multimodal therapy is urgently needed to improve the long-term survival of PDA patients. METHODS: Six eligible PDA patients underwent multimodal therapy comprising dendritic cells (DCs) pulsed with Wilms' tumor 1 (WT1) peptide (DC/WT1-I) restricted by the human leukocyte antigen (HLA) class I (A*24:02 or A*02:06) allele, chemotherapy, radiation, and/or surgery...
September 19, 2018: Human Vaccines & Immunotherapeutics
https://read.qxmd.com/read/30215041/identifying-the-role-of-neutrophil-to-lymphocyte-ratio-and-platelets-to-lymphocyte-ratio-as-prognostic-markers-in-patients-undergoing-resection-of-pancreatic-ductal-adenocarcinoma
#14
Alexandros Giakoustidis, Kyriakos Neofytou, Mafalda Costa Neves, Dimitrios Giakoustidis, Eleni Louri, David Cunningham, Satvinder Mudan
Backgrounds/Aims: It is important to point out that the identification of inflammation is an essential component of the pathogenesis and the progression of cancer. In this study, we analysed the neutrophil-to-lymphocyte ratio (NLR) and the platelets-to-lymphocyte ratio (PLR), with an overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC), who were treated with a resection following or not following a procedure of neoadjuvant chemotherapy/chemoradiation. We intended to identify the significance of the role of NLR and PLR, as prognostic markers in patients undergoing surgery for PDAC...
August 2018: Annals of Hepato-Biliary-Pancreatic Surgery
https://read.qxmd.com/read/30196571/narca-a-novel-prognostic-scoring-system-using-neutrophil-albumin-ratio-and-ca19-9-to-predict-overall-survival-in-palliative-pancreatic-cancer
#15
Samuel J Tingle, George R Severs, Michael Goodfellow, John A Moir, Steven A White
BACKGROUND AND OBJECTIVES: Several serum based-markers and ratios have been investigated for their prognostic value in pancreatic ductal adenocarcinoma (PDAC). This cohort study aimed to combine these into a novel prognostic scoring system. METHODS: A retrospective cohort study was performed on 145 patients with unresectable histologically-confirmed PDAC. Based on the existing literature the following markers were investigated: neutrophil-lymphocyte ratio (NLR), neutrophil-albumin ratio (NAR), platelet-lymphocyte ratio (PLR), fibrinogen, and Ca19-9...
September 2018: Journal of Surgical Oncology
https://read.qxmd.com/read/30194208/the-combination-of-neutrophil-to-lymphocyte-ratio-and-serum-carbohydrate-antigen-19-9-level-as-a-prognostic-indicator-in-patients-with-recurrent-pancreatic-cancer
#16
Teruhisa Sakamoto, Hiroaki Saito, E I Uchinaka, Masaki Morimoto, Masataka Amisaki, Naruo Tokuyasu, Soichiro Honjo, Keigo Ashida, Yoshiyuki Fujiwara
BACKGROUND/AIM: We retrospectively investigated the relationship between prognosis and combined neutrophil-to-lymphocyte ratio (NLR) and serum carbohydrate antigen 19-9 (CA19-9) levels in patients with recurrent pancreatic cancer. PATIENTS AND METHODS: We enrolled 66 patients whose pancreatic cancer recurred. RESULTS: Based on ROC analysis results, the patients were divided into NLRHigh (NLR ≥1.69) or NLRLow (NLR <1.69), and into CA19-9High (CA19-9 ≥107...
September 2018: Anticancer Research
https://read.qxmd.com/read/30172265/-prognostic-value-of-neutrophil-to-lymphocyte-ratio-in-patients-with-lung-adenocarcinoma-treated-with-radical-dissection
#17
Gaoxiang Wang, Ran Xiong, Hanran Wu, Guangwen Xu, Caiwei Li, Xiaohui Sun, Mingran Xie
BACKGROUND: Previous studies have shown that the neutrophil-to-lymphocyte ratio (NLR) has a significant impact on the prognosis of many malignant tumors such as gastric cancer, colorectal cancer and pancreatic cancer, but the study on the prognosis of patients with resectable lung adenocarcinoma is less. The aim of this study is to investigate the correlation between the NLR and the clinicopathologic features of adenocarcinoma of lung patients who underwent radical pneumonectomy. Furthermore, this study aimed to clarify the predictive and prognostic significance of NLR in patients who underwent pneumonectomy for lung adenocarcinoma...
August 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://read.qxmd.com/read/30167864/anergic-natural-killer-cells-educated-by-tumor-cells-are-associated-with-a-poor-prognosis-in-patients-with-advanced-pancreatic-ductal-adenocarcinoma
#18
Chao Yang, He Cheng, Yiyin Zhang, Kun Fan, Guopei Luo, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kaizhou Jin, Zhengshi Wang, Xianjun Yu, Chen Liu
INTRODUCTION: Natural killer cells (NK) are often believed to play a positive role in the antitumor immune response. However, this is not the case for patients with advanced pancreatic cancer. This study was performed to determine the unique subtype of "educated" NK cells and their prognostic value in patients with advanced pancreatic cancer. METHODS: We divided 378 eligible patients into a derivation cohort (September 2010 to December 2014, n = 239) and a validation cohort (January 2015 to April 2016, n = 139)...
August 22, 2018: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/30151266/retrospective-comparison-of-the-efficacy-and-the-toxicity-of-standard-and-modified-folfirinox-regimens-in-patients-with-metastatic-pancreatic-adenocarcinoma
#19
Victor Hugo Fonseca de Jesus, Marcos Pedro Guedes Camandaroba, Mauro Daniel Spina Donadio, Audrey Cabral, Thiago Pimentel Muniz, Luciana de Moura Leite, Lucas Ferreira Sant'Ana
Background: FOLFIRINOX stands a major breakthrough in the management of metastatic pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported using standard FOLFIRINOX. We aimed to compare survival outcomes, response rates and toxicity of patients treated with standard or modified FOLFIRINOX in MPA. Methods: We included patients aged ≥18 years old, with pathologically confirmed MPA, treated with FOLFIRINOX in the first-line setting...
August 2018: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/30097739/clinical-impact-of-neoadjuvant-therapy-on-nutritional-status-in-pancreatic-cancer
#20
Mitsuru Tashiro, Suguru Yamada, Fuminori Sonohara, Hideki Takami, Masaya Suenaga, Masamichi Hayashi, Yukiko Niwa, Chie Tanaka, Daisuke Kobayashi, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Tsutomu Fujii, Yasuhiro Kodera
BACKGROUND: The association between neoadjuvant therapy (NAT) and nutritional status in pancreatic cancer (PC) is unknown. OBJECTIVE: The aim of this study was to assess the impact of NAT on nutritional status. METHODS: Overall, 161 patients who underwent pancreatoduodenectomy for PC between August 2010 and March 2017 were enrolled and were divided into two groups: the neoadjuvant group (NAG; n = 67) and the control group (CG; n = 94)...
October 2018: Annals of Surgical Oncology
keyword
keyword
162937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"